Carla-Liana Scânteie1, Daniel-Corneliu Leucuţa2, Cristina Ghervan3. 1. Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Emergency County Hospital Alba-Iulia, Alba, Romania. 2. Department of Medical Informatics and Biostatistics, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. 3. Department of Endocrinology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Clinical Emergency County Hospital, Romania.
Abstract
Background and aim: Identifying the predictive factors of tumoral and hormonal answer of somatotropinomas to the medical treatment with somatostatin analogs represent an important element for treatment management. The aim of this study was to assess the therapeutic answer of the somatotropinomas according to the T2-weighted signal intensity on the MRI. Methods: We included 31 acromegalic patients, mean age 51.35 ± 10.37 years, who underwent surgery. The patients were divided according to the T2-weighted MRI signal intensity - hypointense, hyperintense and isointense - of the GH-secreting pituitary adenoma and were evaluated after surgery, 3, 6 and 12 months with somatostatin analogs therapy. Results: 16 (51.61%) somatropinomas were hypointense, 9 (29.03%) were hyperintense and 6 (19.35%) were isointense. The median IGF-1 and GH level decreased significantly in macroadenomas (p<0.001, p<0.001, respectively), whereas GH decreased significantly only in microadenomas (p=0.010). A significant statistical correlation was found between IGF-1 or GH levels and tumor volume before surgery (Spearman=0.38, p<0.001; Spearman=0.64, p<0.001, respectively) and after surgery (Spearman=0.61, p=0.001; Spearman=0.74, p<0.001). The percentage of optimally controlled patients increased from 12.9% after surgery, to 28.57% after 12 months with somatostatin analogs. The highest percentage of optimally controlled patients with somatostatin analogs treatment was in hypointense somatotropinomas (50%). Conclusion: The T2-weighted MRI signal intensity classifies the somatotropinomas into groups with certain evolutive and medical treatment response particularities, of which we found that the hypointense somatotropinomas have a better therapeutic response after surgery and after long-term treatment with somatostatin analogs.
Background and aim: Identifying the predictive factors of tumoral and hormonal answer of somatotropinomas to the medical treatment with somatostatin analogs represent an important element for treatment management. The aim of this study was to assess the therapeutic answer of the somatotropinomas according to the T2-weighted signal intensity on the MRI. Methods: We included 31 acromegalic patients, mean age 51.35 ± 10.37 years, who underwent surgery. The patients were divided according to the T2-weighted MRI signal intensity - hypointense, hyperintense and isointense - of the GH-secreting pituitary adenoma and were evaluated after surgery, 3, 6 and 12 months with somatostatin analogs therapy. Results: 16 (51.61%) somatropinomas were hypointense, 9 (29.03%) were hyperintense and 6 (19.35%) were isointense. The median IGF-1 and GH level decreased significantly in macroadenomas (p<0.001, p<0.001, respectively), whereas GH decreased significantly only in microadenomas (p=0.010). A significant statistical correlation was found between IGF-1 or GH levels and tumor volume before surgery (Spearman=0.38, p<0.001; Spearman=0.64, p<0.001, respectively) and after surgery (Spearman=0.61, p=0.001; Spearman=0.74, p<0.001). The percentage of optimally controlled patients increased from 12.9% after surgery, to 28.57% after 12 months with somatostatin analogs. The highest percentage of optimally controlled patients with somatostatin analogs treatment was in hypointense somatotropinomas (50%). Conclusion: The T2-weighted MRI signal intensity classifies the somatotropinomas into groups with certain evolutive and medical treatment response particularities, of which we found that the hypointense somatotropinomas have a better therapeutic response after surgery and after long-term treatment with somatostatin analogs.
Authors: Pamela U Freda; Laurence Katznelson; Aart Jan van der Lely; Carlos M Reyes; Shouhao Zhao; Daniel Rabinowitz Journal: J Clin Endocrinol Metab Date: 2005-05-10 Impact factor: 5.958
Authors: Iulia Potorac; Patrick Petrossians; Adrian F Daly; Franck Schillo; Claude Ben Slama; Sonia Nagi; Mouna Sahnoun; Thierry Brue; Nadine Girard; Philippe Chanson; Ghaidaa Nasser; Philippe Caron; Fabrice Bonneville; Gérald Raverot; Véronique Lapras; François Cotton; Brigitte Delemer; Brigitte Higel; Anne Boulin; Stéphan Gaillard; Florina Luca; Bernard Goichot; Jean-Louis Dietemann; Albert Beckers; Jean-François Bonneville Journal: Endocr Relat Cancer Date: 2015-01-02 Impact factor: 5.678
Authors: Laurence Katznelson; Edward R Laws; Shlomo Melmed; Mark E Molitch; Mohammad Hassan Murad; Andrea Utz; John A H Wass Journal: J Clin Endocrinol Metab Date: 2014-10-30 Impact factor: 5.958